What is Babson Diagnostics?
Babson Diagnostics is dedicated to revolutionizing diagnostic blood testing, making it more accessible, convenient, and less intrusive for consumers. The company is developing a proprietary technological ecosystem designed to deliver accurate results with an improved patient experience. By integrating transformative diagnostic technology with a retail-centric business model, Babson aims to enhance routine health monitoring and overall customer well-being. Currently, the company is engaged in clinical studies with retail pharmacies to validate its innovative approach, with findings intended for peer-reviewed publication. Founded in 2017 and headquartered in Austin, Texas, Babson Diagnostics is focused on democratizing health insights.
How much funding has Babson Diagnostics raised?
Babson Diagnostics has raised a total of $44.7M across 2 funding rounds:
Series A
$13.7M
Series B
$31M
Series A (2020): $13.7M with participation from LAGO Consulting & Services LLC, Prism Ventures, Siemens Healthineers Company, and Genesis Merchant Solutions LLC
Series B (2021): $31M led by Siemens Healthineers, Prism Ventures, and Emerald Development Managers
Key Investors in Babson Diagnostics
Emerald Development Managers
Emerald Development Managers is a venture capital firm that invests in exceptional scientific and engineering teams focused on solving real-world problems. They specialize in sectors such as life sciences, enterprise software, cybersecurity, industrial technology, and sustainability.
Prism Ventures
Prism Ventures is a U.S. company providing support services to the Oil and Gas sectors, founded in 1988. They specialize in well log digitizing, synthetic seismograms, and seismic digitizing, maintaining long-standing relationships with clients in the energy industry.
Siemens Healthineers
Siemens Healthineers is a leading medical technology company focused on advancing healthcare through innovative solutions in areas such as diagnostic imaging, laboratory diagnostics, and advanced therapies. They are committed to improving patient outcomes and enabling healthcare providers to deliver better care.
What's next for Babson Diagnostics?
With its recent enterprise-level funding, Babson Diagnostics is poised to accelerate its commercialization efforts and further refine its diagnostic technology. The capital will likely support scaling operations, expanding clinical validation partnerships, and preparing for broader market entry. The company's strategic focus on accuracy, convenience, and accessibility, combined with its innovative business model, suggests a strong potential for disruption in the healthcare diagnostics landscape. Continued investment and strategic alliances will be key to realizing its vision of making routine health monitoring a seamless part of everyday life.
See full Babson Diagnostics company page
